Heyltex Corporation to Become Exclusive Distributor of Thyr...( Partnership with Fleming Pharmaceutic...),Health

Partnership with Fleming Pharmaceuticals to increase access to radiological threat antidote

WASHINGTON, Feb. 25 /PRNewswire-USNewswire/ -- Today, Heyltex Corporation announced an agreement in principle with Fleming Pharmaceuticals for the exclusive distribution of ThyroShield(R) in the United States. ThyroShield(R) Potassium Iodide Oral Solution is a ready-to-use, liquid medicine that protects infants, children, and adults at risk of exposure to radioactive iodine. It is the only FDA-approved liquid potassium iodine product indicated for thyroid protection in a radiation emergency.

By saturating the thyroid gland with potassium iodide, ThyroShield(R) prevents radioactive iodine from being absorbed by the thyroid gland. The product will be available to families through their local pharmacist or online. It is also supplied to the 31 states with commercial nuclear power plants through the Nuclear Regulatory Commission's Program to supply potassium iodide within the 10-mile Emergency Planning Zone and a part of the Department of Health and Human Service's Project BioShield.

"This is an exciting development for Heyltex, as we expand our radiological countermeasure product offerings in the homeland security space," said Alexander Heyl, CEO of Heyltex Corporation. "We're proud that Heyltex is making Americans safer by making ThyroShield(R) available in the event of a radiological attack."

"We are pleased to forge this partnership with Heyltex," said Phill Dritsas, Fleming's President. "This further expands our commitment to ensure that ThyroShield(R) is widely available to meet homeland security needs."

ThyroShield(R) will be the second product addition to the Heyltex portfolio in 2009. Earlier this year, the company began the distribution of Cool Comfort Technology by 32 Degrees(TM) - a new, lightweight, high-absorption cooling fabric that is used in a variety of disaster respons
'/>"/>